Ryzneuta (efbemalenograstim)
Research Synopsis
- Ryzneuta (efbemalenograstim) is a recombinant fusion protein that serves as a treatment for chemotherapy-induced neutropenia, particularly aiming to lower the risk of febrile neutropenia.
- It received its first approval in China on May 6, 2023, specifically for adult patients with non-myeloid malignant tumors undergoing chemotherapy.
- Ryzneuta is currently under review for approval in both the EU and the USA, highlighting its potential for wider accessibility in cancer treatment.
- Recent research has demonstrated its effectiveness in reducing severe neutropenia duration and lowering febrile neutropenia incidence in breast cancer patients compared to placebo.
- A phase 2 trial has shown that efbemalenograstim is not inferior to pegfilgrastim in managing neutropenia, with comparable safety profiles and low rates of febrile neutropenia.
- Ongoing multicenter phase III trials have further validated its efficacy, focusing on its administration comparisons with other standard therapies, such as filgrastim.
- Emerging therapies like Ryzneuta are crucial in addressing gaps in the treatment of chemotherapy-induced complications, aiming to enhance patient outcomes and reduce disparities.
- Clinical studies indicate that Ryzneuta may offer a more convenient administration schedule with similar outcomes to existing medications, suggesting improved patient adherence.
- Overall, Ryzneuta has garnered positive sentiment among researchers, indicating a shift towards integrating innovative agents for managing chemotherapy-associated neutropenia.
- The continued research and clinical trials surrounding Ryzneuta support its potential as a valuable option in oncology, strengthening treatment efficacy against chemotherapy-related complications.
Ryzneuta (efbemalenograstim)
Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
The impact of new and emerging agents on outcomes for febrile neutropenia: addressing clinical gaps.
London, UK
2 hours ago
1 Received
- Chemotherapy is effective for treating cancer, but chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) limit treatment effectiveness by causing delays in receiving full doses of medication.
- New biosimilars and therapies, like long-acting G-CSF products and innovative agents, are emerging, helping to improve access, reduce costs, and maintain efficacy in the treatment of CIN.
- Ongoing clinical trials are investigating these new agents to potentially enhance patient outcomes and decrease disparities in access to effective cancer treatments.
$100 - $150
Hourly Rate
Efbemalenograstim Alfa: First Approval.
London, UK
2 hours ago
1 Received
- Efbemalenograstim alfa (Ryzneuta) is a recombinant fusion protein developed by Evive Biotech to treat neutropenia caused by chemotherapy, administered via subcutaneous injection.
- * On May 6, 2023, it was approved in China for adult patients with non-myeloid malignant tumors undergoing treatment with chemotherapy that can lead to febrile neutropenia.
- * The drug is currently under review for approval in the EU and USA, and the article highlights significant milestones in its development leading to the initial approval.
$100 - $150
Hourly Rate
Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial.
London, UK
2 hours ago
1 Received
- A study was conducted to assess the safety and effectiveness of efbemalenograstim alfa in preventing febrile neutropenia in breast cancer patients undergoing chemotherapy.
- The trial involved 122 participants who received either efbemalenograstim alfa or a placebo during their chemotherapy cycles, with significant findings showing reduced duration of severe neutropenia and lower incidence of febrile neutropenia in the treatment group.
- The results indicated that efbemalenograstim alfa not only reduced complications associated with chemotherapy but also demonstrated a favorable safety profile for patients.
$100 - $150
Hourly Rate
Efbemalenograstim alfa not inferior to pegfilgrastim in providing neutrophil support in women with breast cancer undergoing myelotoxic chemotherapy: results of a phase 2 randomized, multicenter, open-label trial.
London, UK
2 hours ago
1 Received
- The study aimed to assess the safety and effectiveness of efbemalenograstim alfa for boosting neutrophil levels in breast cancer patients receiving chemotherapy, focusing on a phase 2 trial.
- A total of 232 patients were treated with different chemotherapy regimens and randomized to receive either efbemalenograstim alfa or pegfilgrastim, with results indicating efbemalenograstim alfa showed comparable outcomes to pegfilgrastim in managing neutropenia.
- The findings revealed that efbemalenograstim alfa had a similar safety profile to pegfilgrastim, with low instances of febrile neutropenia, suggesting it could be a viable option for neutrophil support during chemotherapy.
$100 - $150
Hourly Rate
Ryzneuta for prevention of febrile neutropenia.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer.
London, UK
2 hours ago
1 Received
- F-627 (efbemalenograstim alfa) is a new long-acting G-CSF designed to reduce neutropenia in patients undergoing chemotherapy, and this study compared its efficacy and safety against the standard treatment, filgrastim.
- In a multicenter, randomized trial with 239 patients, participants received either a single injection of F-627 or daily injections of filgrastim after chemotherapy with epirubicin and cyclophosphamide, focusing on the duration of severe neutropenia as the primary endpoint.
- Results showed that both treatments had similar effects on the duration of severe neutropenia, with F-627 being well tolerated and possibly offering some advantages in terms of a lower incidence and shorter
$100 - $150
Hourly Rate
Efbemalenograstim Alfa-vuxw.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate